FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296577881> ?p ?o ?g. }

• W4296577881 endingPage "e737" @default.
• W4296577881 startingPage "e725" @default.
• W4296577881 abstract "BackgroundSymptomatic hand osteoarthritis is more common in women than in men, and its incidence increases around the age of menopause, implicating oestrogen deficiency. No randomised controlled trials of hormone replacement therapy (HRT) have been done in people with hand osteoarthritis. We aimed to determine the feasibility and acceptability of a form of HRT (conjugated oestrogens plus bazedoxifene) in post-menopausal women with painful hand osteoarthritis.MethodsThe HOPE-e feasibility study was a randomised, double-blind, placebo-controlled trial, for which we recruited women aged 40–65 years, for whom 1–10 years had passed after their final menstrual period, with definite hand osteoarthritis and at least two painful hand joints. Participants were recruited across three primary or secondary care sites and from the community and were randomly assigned (1:1) to receive conjugated oestrogens plus bazedoxifene or placebo, orally once every day for 24 weeks, before weaning for 4 weeks until the end of the study. The primary feasibility outcomes were rates of identification, recruitment, randomisation, retention, and compliance of eligible participants, and the likelihood of unmasking. The secondary objective was to generate proof-of-concept quantitative and qualitative data on the acceptability of proposed clinical outcomes for a full trial and adverse events. We used an intention-to-treat analysis, and criteria for progression to a full trial were pre-defined as recruitment of at least 30 participants across all sites in 18 months; a dropout rate of less than or equal to 30% of randomised individuals; and acceptability to the majority of participants, including acceptable rates of adverse events. Due to the COVID-19 pandemic, the recruitment window was reduced to 12–15 months. A proportionately reduced minimum sample size of 22 was judged to be sufficient to test feasibility. This trial was registered at ISRCTN, ISRCTN12196200.FindingsFrom May 9, 2019 to Dec 31, 2020, 434 enquiries or referrals were received. We did 96 telephone pre-screens; of the 35 eligible participants, seven were excluded as ineligible at the telephone or face-to-face screening and 28 (80% [95% CI 63–92]) were randomly assigned. Of the 406 who were not randomly assigned, 250 (62%) were ineligible (with contraindicated medications accounting for 50 [20%] of these), 101 (25%) did not respond to further enquiries, and 55 (14%) chose not to proceed (with the most common reason being not wanting to take a hormone-based drug). All 28 randomised participants completed all follow-up assessments with high compliance and outcome measure completeness. All three adverse event-related treatment withdrawals were in the placebo group. No serious adverse events were reported. Participants and investigators were successfully masked (participant Bang's blinding index placebo group 0·50 [95% CI 0·25–0·75]). The trial met the prespecified criteria for progression to a full trial.InterpretationThis first-ever feasibility study of a randomised controlled trial of HRT for post-menopausal women with painful hand osteoarthritis met its progression criteria, although it was not powered to detect a clinical effect. This outcome indicates that a full trial of an HRT in this population is feasible and acceptable and identifies potential refinements with regard to the design of such a trial.FundingResearch for Patient Benefit programme, National Institute for Health Research." @default.
• W4296577881 created "2022-09-22" @default.
• W4296577881 creator A5003452764 @default.
• W4296577881 creator A5005297268 @default.
• W4296577881 creator A5006524973 @default.
• W4296577881 creator A5009213464 @default.
• W4296577881 creator A5035704725 @default.
• W4296577881 creator A5039229275 @default.
• W4296577881 creator A5041416682 @default.
• W4296577881 creator A5041979463 @default.
• W4296577881 creator A5046944970 @default.
• W4296577881 creator A5047802959 @default.
• W4296577881 creator A5050919845 @default.
• W4296577881 creator A5056573091 @default.
• W4296577881 creator A5058287929 @default.
• W4296577881 creator A5058578454 @default.
• W4296577881 creator A5064224283 @default.
• W4296577881 creator A5075349431 @default.
• W4296577881 creator A5075464551 @default.
• W4296577881 creator A5075913739 @default.
• W4296577881 creator A5076931109 @default.
• W4296577881 creator A5081242915 @default.
• W4296577881 creator A5086744726 @default.
• W4296577881 creator A5087650984 @default.
• W4296577881 creator A5088307413 @default.
• W4296577881 date "2022-10-01" @default.
• W4296577881 modified "2023-09-27" @default.
• W4296577881 title "Hormone replacement therapy (conjugated oestrogens plus bazedoxifene) for post-menopausal women with symptomatic hand osteoarthritis: primary report from the HOPE-e randomised, placebo-controlled, feasibility study" @default.
• W4296577881 cites W1963826852 @default.
• W4296577881 cites W1964161175 @default.
• W4296577881 cites W1980618271 @default.
• W4296577881 cites W1992324790 @default.
• W4296577881 cites W1999576231 @default.
• W4296577881 cites W1999691424 @default.
• W4296577881 cites W2009429260 @default.
• W4296577881 cites W2016328111 @default.
• W4296577881 cites W2032624822 @default.
• W4296577881 cites W2038345799 @default.
• W4296577881 cites W2040105893 @default.
• W4296577881 cites W2045617603 @default.
• W4296577881 cites W2057582645 @default.
• W4296577881 cites W2060775470 @default.
• W4296577881 cites W2071718640 @default.
• W4296577881 cites W2081859324 @default.
• W4296577881 cites W2088306158 @default.
• W4296577881 cites W2096388167 @default.
• W4296577881 cites W2103495251 @default.
• W4296577881 cites W2137904825 @default.
• W4296577881 cites W2159203244 @default.
• W4296577881 cites W2162957019 @default.
• W4296577881 cites W2171290372 @default.
• W4296577881 cites W2177920170 @default.
• W4296577881 cites W2327713037 @default.
• W4296577881 cites W2766979786 @default.
• W4296577881 cites W2789500439 @default.
• W4296577881 cites W2789625780 @default.
• W4296577881 cites W2802358407 @default.
• W4296577881 cites W2895008287 @default.
• W4296577881 cites W2897749763 @default.
• W4296577881 cites W2990769288 @default.
• W4296577881 cites W3159389642 @default.
• W4296577881 cites W3173939969 @default.
• W4296577881 cites W4211142475 @default.
• W4296577881 cites W4230038400 @default.
• W4296577881 cites W4237427043 @default.
• W4296577881 cites W4288058404 @default.
• W4296577881 doi "https://doi.org/10.1016/s2665-9913(22)00218-1" @default.
• W4296577881 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36341025" @default.
• W4296577881 hasPublicationYear "2022" @default.
• W4296577881 type Work @default.
• W4296577881 citedByCount "2" @default.
• W4296577881 countsByYear W42965778812022 @default.
• W4296577881 countsByYear W42965778812023 @default.
• W4296577881 crossrefType "journal-article" @default.
• W4296577881 hasAuthorship W4296577881A5003452764 @default.
• W4296577881 hasAuthorship W4296577881A5005297268 @default.
• W4296577881 hasAuthorship W4296577881A5006524973 @default.
• W4296577881 hasAuthorship W4296577881A5009213464 @default.
• W4296577881 hasAuthorship W4296577881A5035704725 @default.
• W4296577881 hasAuthorship W4296577881A5039229275 @default.
• W4296577881 hasAuthorship W4296577881A5041416682 @default.
• W4296577881 hasAuthorship W4296577881A5041979463 @default.
• W4296577881 hasAuthorship W4296577881A5046944970 @default.
• W4296577881 hasAuthorship W4296577881A5047802959 @default.
• W4296577881 hasAuthorship W4296577881A5050919845 @default.
• W4296577881 hasAuthorship W4296577881A5056573091 @default.
• W4296577881 hasAuthorship W4296577881A5058287929 @default.
• W4296577881 hasAuthorship W4296577881A5058578454 @default.
• W4296577881 hasAuthorship W4296577881A5064224283 @default.
• W4296577881 hasAuthorship W4296577881A5075349431 @default.
• W4296577881 hasAuthorship W4296577881A5075464551 @default.
• W4296577881 hasAuthorship W4296577881A5075913739 @default.
• W4296577881 hasAuthorship W4296577881A5076931109 @default.
• W4296577881 hasAuthorship W4296577881A5081242915 @default.
• W4296577881 hasAuthorship W4296577881A5086744726 @default.
• W4296577881 hasAuthorship W4296577881A5087650984 @default.
• W4296577881 hasAuthorship W4296577881A5088307413 @default.
• W4296577881 hasBestOaLocation W42965778811 @default.

• next